

Express Mail Label No.: EJ770265638US
Date of Deposit: November 24, 1999



Attorney Docket No: 19904-001 (BREESE-1)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Chagnaud, *et al.*

ASSIGNEE: Centre National de la Recherche Scientifique

U.S. SERIAL 09/331,980
NUMBER:

INTERNATIONAL December 23, 1997

FILING DATE:

FOR: ANTIBODIES SPECIFICALLY RECOGNIZING A NITROSYLATED PROTEIN,
THEIR METHOD OF PREPERATION, THERPAEUTIC USE AND
DIAGNOISIS

November 24, 1999
Boston, Massachusetts

Box Missing Parts

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

U.S. Patent Documents:

<u>U.S. Patent Document No.</u>	<u>Issue Date</u>	<u>Name of Applicant(s)</u>
4,835,258	05/30/89	Hollenberg, <i>et al.</i>

Foreign Patent Documents:

<u>Patent/Publication No.</u>	<u>Name of Patentee(s) or Applicant(s)</u>	<u>Date of Publication</u>
WO 96/04311	University of Alabama at Birmingham.	03/23/95
WO 95/07691	Brigham and Women's Hospital	02/15/96
EP 0 736 770 A3	Roland Maes	05/02/97
WO 94/11348	Trustees of the University of Pennsylvania	05/26/94

Other Prior Art – Non Patent Literature Documents:

Yao, *et al.*, 1996. Antibodies that recognize nitrotyrosine, *Methods Enzymol.* **269**: 201-209.
Wizemann, *et al.*, 1994. Production of nitric oxide and peroxynitrite in the lung during acute endotoxemia, *J. Leukocyte Biol.* **56**: 759-766.
Mnaimneh, *et al.*, 1997. Albumin nitrosylated by activated macrophages possesses antiparasitic effects neutralized by anti-NO-acetylated-cysteine antibodies, *J. Immunol.* **158**: 308-314.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.


Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached modified Form PTO-1449. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed modified Form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any fees that may be due to Deposit Account No. 50-0311 (Reference No. 19940-001; BREESE-1).

Respectfully submitted,



Ivor R. Elrifi (Reg. No. 39,529)
Michel Morency (Limited Recognition)
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: November 24, 1999